Analysts Q&A Summary:
1) Analyst: Geoff Meacham, Citibank
– The question: Concerns about tariffs and Merck’s mitigating strategies.
– The response: Rob Davis explained that $200 million in existing tariffs are included in earnings and discussed strategies to manage potential future tariffs. He detailed investments already begun to rebalance supply chains, with a focus on US-based manufacturing to mitigate potential impacts without relying on price adjustments.
2) Analyst: Kim Anderson, Bank of America
– The question: Inquiry about Merck’s long-term guidance and concerns over KEYTRUDA patent expiration effects on valuations.
– The response: Rob Davis emphasized the strong pipeline, highlighting $50 billion in potential commercial opportunities through new products, though there are no current plans for detailed financial guidance.
3) Analyst: Luisa Hector, Berenberg
– The question: Asked about changes at FDA and HHS, especially concerning vaccines.
– The response: Dean Lee stated that recent regulatory activities remain on track and that personnel changes have not yet created any timeline shifts.
4) Analyst: Vamil Divan, Guggenheim Securities
– The question: Focused on Merck’s business development environment and potential international pricing regulations.
– The response: Rob Davis reassured that business development remains a priority despite market uncertainty, noting willingness to align on market realities.
5) Analyst: Chris Schott, JPMorgan
– The question: Discussed Gardasil’s future as a single-dose vaccine and manufacturing efforts related to tariffs.
– The response: Rob Davis and Caroline discussed the clinical evidence required to change Gardasil’s dosage recommendations and spoke on extensive strategies for manufacturing adjustments to mitigate tariffs.
6) Analyst: James Shin, Deutsche Bank
– The question: Further inquiries on US investments and developments in PD-one VEGF.
– The response: Rob Davis confirmed strong ongoing US investments regardless of tax changes, and Dean Lee acknowledged the significance of emerging PD-one VEGF data for strategy development.
7) Analyst: Steve Schuller, TD Cowen
– The question: Questioned changes in Gardasil’s growth expectations and potential 2025 trough.
– The response: Caroline highlighted strong growth excluding China and reaffirmed confidence in future growth despite withdrawing the $11 billion target for Gardasil.
8) Analyst: Alex Hammond, Wolfe Research
– The question: Asked about Gardasil’s ACIP recommendation changes from 9 to 12 years.
– The response: A positive development seen for patient adherence, expected to reinforce existing vaccinations, though not forecasted as a large upside.
9) Analyst: Umer Raffat, Evercore
– The question: Inquiry about IP management for KEYTRUDA subQ.
– The response: Rob Davis declined to disclose specifics for proprietary reasons.
10) Analyst: Akish Tewari, Jefferies
– The question: Speculated the impact of theoretical 25% tariffs and mitigation strategies.
– The response: Rob Davis reassured that comprehensive planning and inventory management are in place to mitigate potential impacts without speculating on tariff specifics.
11) Analyst: Mohit Bansal, Wells Fargo
– The question: Questioned Merck’s business development strategy and perception of chasing front-runners.
– The response: Dean Lee and Rob Davis highlighted Merck’s focus on both innovative and combinatory strategies across their pipeline to drive growth.
Sentiment Score Distribution Table:
| Analyst Name | Firm Name | Sentiment Score (1-10) |
|——————-|———————-|————————|
| Geoff Meacham | Citibank | 7 |
| Kim Anderson | Bank of America | 5 |
| Luisa Hector | Berenberg | 6 |
| Vamil Divan | Guggenheim Securities| 6 |
| Chris Schott | JPMorgan | 7 |
| James Shin | Deutsche Bank | 8 |
| Steve Schuller | TD Cowen | 6 |
| Alex Hammond | Wolfe Research | 7 |
| Umer Raffat | Evercore | 5 |
| Akish Tewari | Jefferies | 6 |
| Mohit Bansal | Wells Fargo | 7 |